The changes in miR-130b levels in human serum and the correlation with the severity of diabetic nephropathy

Diabetes/Metabolism Research and Reviews

Volumn 31, Issue 7, 2015, Pages 717-724

  Lv, Chuan ^a   Zhou, Yue hong ^b   Wu, Can ^a   Shao, Ying ^a   Lu, Can lu ^a   Wang, Qiu Yue ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b Division of Endocrinology Shenyang No 8 Hospital   (China)

Author keywords

Albuminuria; Circulating miR 130b; Diabetic nephropathy; Type 2 diabetes mellitus

Indexed keywords

CREATININE; FIBRONECTIN; HEMOGLOBIN A1C; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LOW DENSITY LIPOPROTEIN; MICRORNA; MICRORNA 130B; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; HIF1A PROTEIN, HUMAN; MIRN130 MICRORNA, HUMAN; TGFB1 PROTEIN, HUMAN;

ADULT; AGED; ALBUMINURIA; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HOMEOSTATIC MODEL ASSESSMENT OF INSULIN RESISTANCE; HUMAN; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; REAL TIME POLYMERASE CHAIN REACTION; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; BLOOD; COMPLICATION; CROSS-SECTIONAL STUDY; DIABETIC NEPHROPATHIES; METABOLISM; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; ALBUMINURIA; BLOOD UREA NITROGEN; CREATININE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRONECTINS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIPOPROTEINS, LDL; MALE; MICRORNAS; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; SEVERITY OF ILLNESS INDEX; TRANSFORMING GROWTH FACTOR BETA1; TRIGLYCERIDES;

EID: 84943664801     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2659     Document Type: Article

References (28)

1. Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 2014; 103(2): 137-149. [PubMed: 24630390]
2. Packham DK, Alves TP, Dwyer JP, et al. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database. Am J Kidney Dis 2012; 59(1): 75-83. [PubMed: 22051245]
3. Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol 2009; 10(2): 126-39. [PubMed: 19165215]
4. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004; 5(7): 522-531. [PubMed: 15211354]
5. Kantharidis P, Wang B, Carew RM, Lan HY. Diabetes complications: the miRNA perspective. Diabetes 2011; 60(7): 1832-1837. [PubMed: 21709278]
6. Shantikumar S, Caporali A, Emanueli C. Role of miRNA in diabetes and its cardiovascular complications. Cardiovasc Res 2012; 93: 583-593. [PubMed: 22065734]
7. Conserva F, Pontrelli P, Accetturo M, Gesualdo L. The pathogenesis of diabetic nephropathy: focus on microRNAs and proteomics. J Nephrol 2013; 26(5): 811-820. [PubMed: 23543479]
8. Zen K, Zhang CY. Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev 2012; 32(2): 326-348. [PubMed: 22383180]
9. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008; 105(30): 10513-10518. [PubMed: 18663219]
10. Ai J, Zhang R, Li Y, et al. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem Biophys Res Commun. 2010; 391(1): 73-77. [PubMed: 19896465]
11. Zampetaki A, Kiechl S, Drozdov I, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 2010; 107(6): 810-817. [PubMed: 20651284]
12. Synetos A, Toutouzas K, Stathogiannis K, et al. MicroRNAs in arterial hypertension. Curr Top Med Chem 2013; 13(13): 1527-1532. [PubMed: 23745804]
13. Ahn J, Lee H, Jung CH, et al. MicroRNA-146b promotes adipogenesis by suppressing the SIRT1-FOXO1 cascade. EMBO Mol Med 2013; 5(10): 1602-1612. [PubMed: 24009212]
14. Lee EK, Lee MJ, Abdelmohsen K, et al. miR-130 suppresses adipogenesis by inhibiting peroxisome proliferator-activated receptor gamma expression. Mol Cell Biol 2011; 31(4): 626-638. [PubMed: 21135128]
15. Zhang R, Zhang Q, Niu J, et al. Screening of microRNAs associated with Alzheimer's disease using oxidative stress cell model and different strains of senescence accelerated mice. J Neurol Sci 2014; 338(1-2): 57-64. [PubMed: 24423585]
16. Saito K, Kondo E, Matsushita M. MicroRNA 130 family regulates the hypoxia response signal through the P-body protein DDX6. Nucleic Acids Res 2011; 39(14): 6086-6099. [PubMed: 21486751]
17. Castro N E, Kato M, Park J T, Natarajan R. Transforming growth factor β1 (TGF-β1) enhances expression of pro-fibrotic genes through a novel signaling cascade and microRNAs in renal mesangial cells. J Biol Chem 2014; 289(42): 29001-29013. [PubMed: 25204661]
18. Ortega FJ, Mercader JM, Catalán V, et al. Targeting the circulating microRNA signature of obesity. Clin Chem 2013; 59(5): 781-792. [PubMed: 23396142]
19. Prats-Puig A, Ortega FJ, Mercader JM, et al. Changes in circulating microRNAs are associated with childhood obesity. J Clin Endocrinol Metab 2013; 98(10): E1655-1660. [PubMed: 23928666]
20. Wang YC, Li Y, Wang XY, et al. Circulating miR-130b mediates metabolic crosstalk between fat and muscle in overweight/obesity. Diabetologia 2013; 56(10): 2275-2285. [PubMed: 23868745]
21. Ortega FJ, Mercader JM, Moreno-Navarrete JM, et al. Profiling of circulating microRNAs reveals common microRNAs linked to type 2 diabetes that change with insulin sensitization. Diabetes Care 2014; 37(5): 1375-1383. [PubMed: 24478399]
22. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289(19): 2560-2572. [PubMed: 12748199]
23. Baltimore D, Boldin MP, O'Connell RM, et al. MicroRNAs: new regulators of immune cell development and function. Nat Immunol 2008; 9(8):839-845. [PubMed: 18645592]
24. Zhang H, Yang H, Zhang C, et al. Investigation of MicroRNA expression in human serum during the aging process. J Gerontol A Biol Sci Med Sci J Gerontol A Biol Sci Med Sci 2015; 70(1): 102-109. [PubMed: 25165030]
25. Liu AM, Yao TJ, Wang W, et al. Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open 2012; 2(2): e000825. [PubMed: 22403344]
26. Chen SC, Tseng CH. Dyslipidemia, kidney disease, and cardiovascular disease in diabetic patients. Rev Diabet Stud 2013; 10(2-3): 88-100. [PubMed: 24380085]
27. Al-Rubeaan K, Youssef AM, Subhani SN, et al. Diabetic nephropathy and its risk factors in a society with a type 2 diabetes epidemic: a Saudi National Diabetes Registry-based study. PLoS One 2014; 9(2): e88956. [PubMed: 24586457]
28. Pan S, Yang X, Jia Y, et al. Microvesicle-shuttled miR-130b reduces fat deposition in recipient primary cultured porcine adipocytes by inhibiting PPAR-g expression. J Cell Physiol 2014; 229(5): 631-9. [PubMed: 24311275]